Neurocrine Biosciences NBIX Income Statement (2009-2026)

NASDAQ NBIX
$174.41 +5.27 (+3.12%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Neurocrine Biosciences Quarterly Income Statement

Periods 71 quarters
Latest Sep 2026

Neurocrine Biosciences reported revenue of $1122.70M and net income of $205.80M for the quarter ended Sep 2026, up 41.2% year over year. This income statement covers 71 quarters of results from Mar 2009 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Mar2009 Jun2009 Sep2009 Dec2009 Mar2010 Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
312.00M310.60M378.20M387.90M412.00M420.40M452.70M498.80M515.20M515.30M590.20M622.10M627.70M572.60M687.50M794.90M805.50M814.50M959.00M1,122.70M
Cost of RevenueCost of Rev
4.10M4.60M4.80M6.10M7.70M8.50M11.50M11.20M8.50M7.50M9.20M8.00M9.30M9.20M10.30M13.00M20.60M13.80M23.20M26.60M
Gross Profit
307.90M306.00M373.40M381.80M404.30M411.90M441.20M487.60M506.70M507.80M581.00M614.10M618.40M563.40M677.20M781.90M784.90M800.70M935.80M1,096.10M
Operating items
Amortization - Intangibles
1.00M1.00M16.40M35.00M
Depreciation & Amortization - TotalDep. & Amort. (Tot)
6.70M9.00M
Research & DevelopmentR&D
87.40M102.20M135.90M107.70M118.00M139.50M145.80M142.20M137.50M159.40M191.10M195.00M185.60M263.20M244.30M250.00M258.20M296.20M326.70M351.80M
Share-based Compensation (IS)Stock Comp.
Selling, General & AdministrativeSG&A
156.50M200.70M182.80M186.30M182.90M242.70M221.80M204.20M218.90M243.10M242.00M234.30M287.80M276.50M286.30M291.60M301.80M318.50M439.70M366.30M
Other Operating ExpensesOther Opex
104.40M4.60M4.80M6.10M7.70M152.40M11.50M11.20M8.50M13.50M11.70M9.00M12.30M9.30M11.30M7.60M34.60M6.40M41.10M64.30M
Operating ExpensesOpex
348.30M307.50M323.50M300.10M308.60M534.60M379.10M357.60M364.90M416.00M444.80M438.30M485.70M549.00M541.90M555.90M594.60M621.10M807.50M791.40M
Operating IncomeOp. Inc
-36.30M3.10M54.70M87.80M103.40M-114.20M73.60M141.20M150.30M99.30M145.40M183.80M142.00M23.60M145.60M239.00M210.90M193.40M151.50M331.30M
Non-operating items
Non Operating Interest Expenses
6.60M2.60M2.20M1.20M1.10M1.10M1.30M1.10M1.10M1.10M2.90M0.30M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
28.40M19.90M-7.40M11.10M-54.40M37.30M-40.10M-29.00M-1.60M-19.90M-16.90M1.90M4.00M28.60M
Interest & Investment IncomeInt & Inv Inc
0.70M1.00M1.60M0.20M1.30M9.80M10.70M14.50M18.90M22.30M22.80M23.40M22.50M21.70M20.60M22.20M25.80M28.10M12.40M5.00M
Other Non Operating IncomeOther Non Op Inc.
-70.00M
Non Operating IncomeNon Op. Inc.
22.50M18.30M-78.00M10.10M14.50M10.90M48.00M-25.60M47.90M-64.80M-46.80M6.50M20.60M-8.90M13.90M52.80M28.50M53.40M10.70M-47.60M
Net income details
EBIT
-36.30M3.10M54.70M87.80M103.40M-114.20M73.60M141.20M150.30M99.30M145.40M183.80M142.00M23.60M145.60M239.00M210.90M193.40M151.50M331.30M
EBT
-13.80M21.40M-23.30M97.90M117.90M-103.30M121.60M115.60M198.20M34.50M98.60M190.30M162.60M14.70M159.50M291.80M239.40M246.80M162.20M283.70M
Tax ProvisionsTaxes
-6.50M7.50M-6.40M29.40M28.90M-26.70M26.10M32.50M50.50M-8.90M33.60M60.50M59.50M6.80M52.00M82.30M85.70M48.90M17.80M77.20M
Income After Tax
-7.30M13.90M-16.90M68.50M89.00M-76.60M95.50M83.10M147.70M43.40M65.00M129.80M103.10M7.90M107.50M209.50M153.70M197.90M144.40M206.50M
Income from Continuing OperationsIncome (Continuing)
-9.40M6.30M-16.90M66.70M95.10M-76.60M97.10M82.50M156.40M39.70M64.20M141.80M94.40M11.10M111.00M210.20M153.60M185.20M149.10M205.80M
Consolidated Net IncomeConsol Net Inc.
-9.40M6.30M-19.80M66.70M95.10M-71.40M97.10M82.50M156.40M39.70M64.20M141.80M94.40M11.10M111.00M210.20M153.60M185.20M149.10M205.80M
Net Income Attributable to Noncontrolling InterestsNCI Net Income
-19.80M-71.40M97.10M39.70M
Income towards Parent CompanyParent Net Inc
-7.30M13.90M-16.90M68.50M89.00M-76.60M95.50M83.10M147.70M43.40M65.00M129.80M103.10M7.90M107.50M209.50M153.70M197.90M144.40M206.50M
Net Income towards Common StockholdersNet Income
-7.30M13.90M-16.90M68.50M89.00M-76.60M95.50M83.10M147.70M43.40M65.00M129.80M103.10M7.90M107.50M209.50M153.70M197.90M144.40M206.50M
Additional items
EPS (Basic)
-0.080.15-0.180.720.93-0.790.980.851.510.430.641.281.030.081.092.111.541.971.432.03
EPS (Diluted)
-0.070.14-0.180.690.90-0.790.950.821.460.420.631.240.990.081.062.041.501.911.391.96
Shares Outstanding
94.60M95.30M95.60M95.80M95.80M97.10M97.60M97.90M97.70M99.80M100.80M101.10M100.40M99.70M99.00M99.40M99.50M100.50M101.00M101.60M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
97.90M97.60M95.60M99.00M98.90M97.10M100.20M101.10M101.00M103.60M103.90M104.30M103.70M102.50M101.00M102.50M102.50M103.40M104.20M105.20M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
94.90M95.50M95.60M96.10M96.50M97.50M97.60M98.20M98.70M100.60M100.90M101.20M99.40M99.00M99.00M99.70M100.10M100.60M101.60M101.30M
EBITDA
-29.20M6.80M59.00M92.00M108.00M-109.00M78.90M146.90M156.10M105.50M152.70M190.30M149.10M31.20M152.90M246.70M218.40M200.70M176.30M375.30M
Interest ExpensesInt Expense
6.60M2.60M2.20M1.20M1.10M1.10M1.30M1.10M1.10M1.10M2.90M0.30M
Tax Rate
35.05%30.03%24.51%21.46%28.11%25.48%34.08%31.79%36.59%46.26%32.60%28.20%35.80%19.81%10.97%27.21%

Neurocrine Biosciences Income Statement API

Pull Neurocrine Biosciences's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=NBIX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY